Ventricular Tachycardia/Fibrillation: Therapeutic Alternatives

JOHN D. FISHER, SOO G. KIM, JAMES A. ROTH, KEVIN J. FERRICK, RICHARD F. BRODMAN, JAY N. GROSS, SEYMOUR FURMAN

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

It is now clear that no single therapy is appropriate for a consecutive series of patients with ventricular tachycardia or ventricular fibrillation (VT/VF). Drug responders by electrophysiological studies, patients who are not inducible following surgery, and patients treated with an implantable cardioverter defibrillator (ICD) all can have similarly low sudden death rates and virtually identical long‐term mortality. However, many patients fail to respond to drugs, and surgical risks are excessive in others, and always higher than for an ICD implant. Nevertheless, overall survival in each of these groups (and probably for patients treated with antitachycardia pacers and ablation) is about 60% at 60 months. Major challenges now are: (1) choosing therapy to maximize risk‐benefit ratio; and (2) treatment of the pump failure and progressive disease that now accounts for most cardiac mortality.

Original languageEnglish (US)
Pages (from-to)370-375
Number of pages6
JournalPacing and Clinical Electrophysiology
Volume14
Issue number2
DOIs
StatePublished - Feb 1991

Keywords

  • antitachycardia
  • implantable cardioverter defibrillator
  • ventricular tachycardia

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Ventricular Tachycardia/Fibrillation: Therapeutic Alternatives'. Together they form a unique fingerprint.

  • Cite this